— Know what they know.
Not Investment Advice

LXEO NASDAQ

Lexeo Therapeutics, Inc. Common Stock
1W: -4.9% 1M: -17.4% 3M: -16.9% YTD: -45.6% 1Y: +48.2%
$5.11
-0.12 (-2.29%)
 
Weekly Expected Move ±8.7%
$4 $5 $5 $6 $6
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 28 · $401.2M mcap · 48M float · 1.89% daily turnover · Short 78% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
32.1 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -40.3%
Cost Advantage
33
Intangibles
25
Switching Cost
38
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. LXEO has No discernible competitive edge (32.1/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. Negative ROIC of -40.3% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$0
Low
$19
Avg Target
$19
High
Based on 9 analyst ratings (12 mo)
Analyst Recommendations
Strong Buy: 0Buy: 5Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$18.78
Analysts9
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-01-13 H.C. Wainwright Mitchell Kapoor $13 $10 -3 +23.2% $8.12
2025-12-17 Raymond James Initiated $25 +174.4% $9.11
2025-12-10 Oppenheimer Leland Gershell Initiated $20 +110.4% $9.51
2025-11-20 Cantor Fitzgerald Initiated $19 +109.0% $9.09
2025-10-21 H.C. Wainwright $15 $13 -2 +41.0% $9.22
2025-10-15 Guggenheim Initiated $30 +252.9% $8.50
2025-10-07 Chardan Capital Initiated $17 +106.1% $8.25
2025-10-07 H.C. Wainwright Initiated $15 +81.8% $8.25
2025-10-07 Leerink Partners Mani Foroohar Initiated $20 +142.4% $8.25
2024-06-12 Robert W. Baird Brian Skorney Initiated $28 +53.9% $18.19

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+
May 22, 2026
DCF
3
ROE
1
ROA
1
D/E
3
P/E
1
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. LXEO receives an overall rating of C+. Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-05-11 C C+
2026-05-01 C- C
2026-04-01 C C-
2026-01-14 C+ C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

Grade A+
Profitability
Balance Sheet
0
Earnings Quality
60
Growth
Value
31
Momentum
Safety
100
Cash Flow

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
10.38
Safe Zone
Piotroski F-Score
3/9
Beneish M-Score
Ohlson O-Score
-0.49
Bankruptcy prob: 38.0%
Moderate
Credit Rating
BBB+
Score: 64.4/100
Trend: Improving
Earnings Quality
OCF/NI: 1.12x
Accruals: 5.0%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. LXEO scores 10.38, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. LXEO scores 3/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. LXEO's implied 38.0% bankruptcy probability is elevated and warrants attention to the balance sheet. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. LXEO receives an estimated rating of BBB+ (score: 64.4/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-4.74x
PEG
-0.05x
P/S
0.00x
P/B
1.79x
P/FCF
-4.73x
P/OCF
EV/EBITDA
-4.70x
EV/Revenue
EV/EBIT
-4.59x
EV/FCF
-4.17x
Earnings Yield
-18.78%
FCF Yield
-21.12%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. LXEO currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
0.977
EBT / EBIT
×
EBIT Margin
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.143
Assets / Equity
=
ROE
-48.1%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. LXEO's ROE of -48.1% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 639 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$5.11
Median 1Y
$2.37
5th Pctile
$0.45
95th Pctile
$12.42
Ann. Volatility
100.3%
25th–75th percentile 5th–95th percentile Median path Historical

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
R. Nolan Townsend
Chief Executive Officer and Director
$632,700 $1,493,488 $3,650,940
Jenny R. Robertson,
J.D. Former Chief Legal Officer
$459,600 $485,613 $2,145,883
Louis Tamayo Financial
ancial Officer
$181,818 $215,550 $1,665,915

CEO Pay Ratio

40:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $3,650,940
Avg Employee Cost (SGA/emp): $90,920
Employees: 500

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
500
0.0% YoY
Revenue / Employee
Profit / Employee
$-199,922
NI: $-99,961,000
SGA / Employee
$90,920
Avg labor cost proxy
R&D / Employee
$127,594
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -12.5% -31.6% -50.3% -76.3% -85.4% -94.9% -99.1% -91.1% -55.0% -48.1% -48.14%
ROA -10.1% -25.7% -40.8% -61.9% -68.6% -76.2% -79.6% -73.2% -48.1% -42.1% -42.11%
ROIC -3.2% -8.2% -13.2% -19.9% -15.9% -17.5% -18.6% -17.1% -45.1% -40.3% -40.33%
ROCE -11.5% -29.2% -46.5% -70.5% -79.1% -88.0% -91.9% -84.5% -39.6% -35.5% -35.55%
Gross Margin
Operating Margin
Net Margin
EBITDA Margin
FCF Margin
OCF Margin
ROE 3Y Avg snapshot only -53.54%
ROA 3Y Avg snapshot only -44.20%
ROIC 3Y Avg snapshot only -74.75%
ROIC Economic snapshot only -30.35%
Cash ROA snapshot only -36.47%
Cash ROIC snapshot only -51.15%
CROIC snapshot only -51.38%
Valuation
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -25.84 -12.23 -9.27 -3.45 -2.21 -1.05 -1.53 -3.86 -7.59 -5.33 -4.741
P/S Ratio 0.000
P/B Ratio 3.23 3.86 4.66 2.63 1.86 0.98 1.50 3.47 3.07 1.89 1.792
P/FCF -26.08 -15.07 -10.70 -4.44 -2.67 -1.30 -1.84 -3.78 -7.66 -4.73 -4.735
P/OCF
EV/EBITDA -18.81 -9.45 -7.56 -2.24 -1.10 -0.03 -0.57 -2.85 -7.19 -4.70 -4.701
EV/Revenue
EV/EBIT -18.16 -9.19 -7.36 -2.19 -1.08 -0.03 -0.56 -2.80 -7.04 -4.59 -4.589
EV/FCF -18.27 -11.30 -8.48 -2.81 -1.30 -0.04 -0.67 -2.74 -7.11 -4.17 -4.175
Earnings Yield -3.9% -8.2% -10.8% -29.0% -45.2% -95.1% -65.2% -25.9% -13.2% -18.8% -18.78%
FCF Yield -3.8% -6.6% -9.3% -22.5% -37.5% -76.8% -54.4% -26.5% -13.1% -21.1% -21.12%
Price/Tangible Book snapshot only 1.889
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 7.21 7.21 7.21 7.21 5.52 5.52 5.52 5.52 11.21 11.21 11.208
Quick Ratio 7.21 7.21 7.21 7.21 5.52 5.52 5.52 5.52 11.21 11.21 11.208
Debt/Equity 0.10 0.10 0.10 0.10 0.08 0.08 0.08 0.08 0.03 0.03 0.032
Net Debt/Equity -0.97 -0.97 -0.97 -0.97 -0.96 -0.96 -0.96 -0.96 -0.22 -0.22 -0.223
Debt/Assets 0.08 0.08 0.08 0.08 0.07 0.07 0.07 0.07 0.03 0.03 0.029
Debt/EBITDA -0.85 -0.33 -0.21 -0.14 -0.10 -0.09 -0.09 -0.10 -0.08 -0.09 -0.090
Net Debt/EBITDA 8.05 3.15 1.98 1.30 1.16 1.04 1.00 1.09 0.56 0.63 0.631
Interest Coverage -282.74 -411.29 -467.09 -550.57 -716.76 -852.87 -750.05 -754.06 -744.89 -727.90 -727.902
Equity Multiplier 1.23 1.23 1.23 1.23 1.26 1.26 1.26 1.26 1.09 1.09 1.089
Cash Ratio snapshot only 3.748
Debt Service Coverage snapshot only -710.634
Cash to Debt snapshot only 7.989
FCF to Debt snapshot only -12.480
Defensive Interval snapshot only 239.0 days
Efficiency & Turnover
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Inventory Turnover
Receivables Turnover
Payables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.20 0.18 0.28 0.281
DSO
DIO 0 0 0 0 0.0 days
DPO 3654 1792 1978 1297 1297.2 days
Cash Conversion Cycle
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue
Net Income -5.9% -2.0% -99.9% -21.2% -1.7% 19.9% 19.95%
EPS -4.7% -1.6% -51.4% 34.3% 56.0% 67.3% 67.35%
FCF -4.8% -2.0% -92.5% -59.1% -21.2% -11.5% -11.48%
EBITDA -6.0% -2.1% -1.0% -21.6% -1.6% 18.4% 18.42%
Op. Income -6.1% -2.0% -99.7% -21.6% -3.3% 15.9% 15.91%
OCF Growth snapshot only -11.35%
Asset Growth snapshot only 82.85%
Equity Growth snapshot only 1.11%
Debt Growth snapshot only -20.54%
Shares Change snapshot only 1.45%
Growth Quality
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 1.00 1.00 1.000
Earnings Stability 0.76 0.47 0.469
Margin Stability
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.500
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.99 0.92 0.920
Earnings Smoothness
ROE Trend 0.08 0.27 0.271
Gross Margin Trend
FCF Margin Trend
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.99 0.80 0.86 0.77 0.83 0.81 0.83 1.02 0.99 1.12 1.120
FCF/OCF 1.01 1.01 1.01 1.01 1.01 1.00 1.00 1.00 1.00 1.00 1.004
FCF/Net Income snapshot only 1.125
CapEx/Revenue
CapEx/Depreciation snapshot only 0.203
Accruals Ratio -0.00 -0.05 -0.06 -0.14 -0.12 -0.15 -0.13 0.01 -0.01 0.05 0.050
Sloan Accruals snapshot only 0.318
Cash Flow Adequacy snapshot only -226.826
Dividends & Buybacks
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -27.4% -43.1% -35.7% -61.1% -37.9% -5.3% -42.2% -19.8% -29.6% -48.6% -48.63%
Total Shareholder Return -27.4% -43.1% -35.7% -61.1% -37.9% -5.3% -42.2% -19.8% -29.6% -48.6% -48.63%
DuPont Factors
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.98 0.977
EBIT Margin
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Equity Multiplier 1.23 1.23 1.23 1.23 1.24 1.24 1.24 1.24 1.14 1.14 1.143
Per Share
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-0.52 $-1.28 $-1.73 $-2.62 $-2.97 $-3.30 $-2.62 $-1.72 $-1.31 $-1.08 $-1.08
Book Value/Share $4.16 $4.06 $3.44 $3.43 $3.53 $3.53 $2.68 $1.92 $3.23 $3.04 $2.85
Tangible Book/Share $4.16 $4.06 $3.44 $3.43 $3.53 $3.53 $2.68 $1.92 $3.23 $3.04 $3.04
Revenue/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-0.51 $-1.04 $-1.50 $-2.04 $-2.47 $-2.67 $-2.19 $-1.76 $-1.30 $-1.21 $-1.21
OCF/Share $-0.51 $-1.03 $-1.48 $-2.02 $-2.45 $-2.66 $-2.18 $-1.75 $-1.29 $-1.21 $-1.21
Cash/Share $4.45 $4.34 $3.68 $3.67 $3.67 $3.67 $2.79 $1.99 $0.83 $0.78 $0.88
EBITDA/Share $-0.50 $-1.24 $-1.68 $-2.55 $-2.91 $-3.24 $-2.57 $-1.69 $-1.28 $-1.08 $-1.08
Debt/Share $0.43 $0.42 $0.35 $0.35 $0.30 $0.30 $0.23 $0.16 $0.10 $0.10 $0.10
Net Debt/Share $-4.02 $-3.93 $-3.33 $-3.32 $-3.37 $-3.37 $-2.56 $-1.83 $-0.72 $-0.68 $-0.68
Academic Models
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 10.384
Altman Z-Prime snapshot only 19.559
Piotroski F-Score 2 2 2 2 2 2 2 1 4 3 3
Beneish M-Score
Ohlson O-Score snapshot only -0.489
ROIC (Greenblatt) snapshot only -49.62%
Net-Net WC snapshot only $2.05
EVA snapshot only $-96405650.00
Credit
Metric Trend Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BBB+
Credit Score 65.72 65.32 65.62 61.74 38.41 32.67 32.53 61.54 64.90 64.36 64.362
Credit Grade snapshot only 8
Credit Trend snapshot only 31.696
Implied Spread (bps) snapshot only 225.000
Industry Credit Rank snapshot only 61
Sector Credit Rank snapshot only 57

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms